Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
Pacira BioSciences is defending its incumbent board against an activist proxy contest by DOMA Perpetual Capital, urging shareholders to vote for its nominees Christopher Christie, Samit Hirawat, and Thomas Wiggans. The company highlights 2025 financial results as evidence of strategic success, reporting record revenue of $726.4 million, GAAP net income of $7.0 million, and Non-GAAP net income of $122.3 million ($2.65 diluted EPS).
Key figures
- Eps
- 0.16
- Eps Beat
- 0
- Revenue
- 726411000
- Guidance
- 5x30 strategy: grow commercial business and build balanced portfolio by 2030; help 3 million patients annually by 2030; five novel programs by 2030; five partnerships by 2030
- Revenue Yoy
- 0
- Gaap net income
- 7034000
- Non gaap eps basic
- 2.74
- Non gaap net income
- 122299000
- Orange book patents
- 21
- Non gaap eps diluted
- 2.65
- Gaap gross margin pct
- 79.4
- Patients treated 2025
- 2500000
- Exparel volume growth yoy
- 6.2
- Non gaap gross margin pct
- 81.2
- Exparel h2 volume growth yoy
- 8
- Stock price increase since strategy launch
- 31
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.